Boston Immune Technologies and Therapeutics Raises $10M Series A Financing

波士顿免疫技术与治疗公司A轮融资1000万美元

2021-03-18 08:30:19 BioSpace

本文共732个字,阅读需2分钟

“This funding, in combination with our recent option and license arrangement with BeiGene, means BITT has the resources to move BIR2101 into the clinic and support proof of concept studies for additional TNF Superfamily targets,” said Russell LaMontagne, Co-founder and Chief Executive Officer of BITT. BITT is exploring clinical trials for BIR2101 as monotherapy and in combination with checkpoint blockade. TNFR2 is highly expressed on the most suppressive cells in the tumor microenvironment and has been identified as a driver of resistance to checkpoint blockade. In multiple murine models, the combination of TNFR2 with PD-1 results in significantly higher cure rates. BITT anticipates filing an IND for BIR2101 by end of 2021. Discovery stage antagonist antibodies for additional TNF Superfamily targets are in development. About Boston Immune Technologies and Therapeutics Boston Immune Technologies and Therapeutics (BITT) is a Boston, MA based company developing a novel class of antagonist antibodies targeting the TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease. BITT is initiating clinical trials for BIR2101, its lead candidate, a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). BITT is also developing additional TNF superfamily antibodies including CD40 antagonists for inflammation and CD30 antagonists for oncology. For more information, visit our website at www.bostonimmunetech.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005784/en/ BITT Contact: Karl Schmieder karl@messaginglab.com 646/515-3392 Source: Boston Immune Technologies and Therapeutics (BITT) View this news release online at: http://www.businesswire.com/news/home/20210317005784/en
BITT联合创始人兼首席执行官拉塞尔·拉蒙塔格尼说:“这笔资金,加上我们最近与BeiGene的选择和许可安排,意味着BITT有资源将BIR2101投入临床,并支持针对更多TNF超家族目标的概念验证研究。 BITT正在探索将BIR2101作为单一疗法和联合检查点封锁进行临床试验。TNFR2在肿瘤微环境中最具抑制性的细胞上高表达,已被鉴定为抵抗检查点封锁的驱动因素。在多个小鼠模型中,TNFR2与PD-1的联合治疗可显著提高治愈率。比特预计将在2021年底为BIR2101提交IND。针对其他TNF超家族靶点的发现阶段拮抗剂抗体正在开发中。 波士顿免疫技术与治疗公司简介 波士顿免疫技术和治疗公司(BITT)是一家总部设在马萨诸塞州波士顿的公司,正在开发一种针对肿瘤坏死因子超家族受体的新型拮抗抗体,用于肿瘤学、炎症、自身免疫和感染性疾病。BITT公司正在启动BIR2101的临床试验,这是一种靶向肿瘤坏死因子受体2(TNFR2)的单克隆抗体。BITT还在开发额外的TNF超家族抗体,包括用于炎症的CD40拮抗剂和用于肿瘤的CD30拮抗剂。欲了解更多信息,请访问我们的网站:www.bostonimunetech.com。 查看businesswire.com上的源版本:https://www.businesswire.com/news/home/20210317005784/en/ 比特接触: 施米德 @messaginglab.com 646/515-3392 资料来源:波士顿免疫技术和治疗(BITT) 请在以下网址联机查看此新闻稿: http://www.businesswire.com/news/home/20210317005784/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文